Few fields sit at as sharp an intersection of biology, engineering, and computing as synthetic biology, and its commercial footprint is expanding rapidly as a result. According to the synthetic biology market report, global valuation is projected to grow from USD 17.12 billion in 2023 to USD 78.74 billion by 2031, reflecting a compound annual growth rate of 21.15% across the forecast period. This growth is being driven by advances in genetic engineering, DNA synthesis, and genome editing technologies that are rapidly expanding what is scientifically and commercially possible.
Market Overview
Synthetic biology merges principles from biology, engineering, and computer science to design and construct artificial biological systems capable of performing functions that may not exist in nature. The field relies on advanced genetic engineering techniques, genome editing tools, and computational modeling to manipulate and reprogram living organisms at the molecular level, with applications spanning healthcare, agriculture, chemicals, energy, and environmental sustainability.
The ambition of the field is substantial: developing novel therapeutics, diagnostics, bio-based materials, and sustainable biofuels through innovative approaches to genetic engineering and biotechnology. As rising investment and expanding government support for biotechnology innovation continue flowing into the sector, alongside a growing wave of synthetic biology startups and academic collaborations, the market’s underlying research base is deepening in tandem with its commercial applications.
Growth Drivers
The expanding range of synthetic biology applications — particularly in multiplexed diagnostics, cellular recording, and therapeutic genome editing — is a major growth catalyst. These advancements support precision medicine by enabling simultaneous analysis of multiple biomarkers and cellular activities with high sensitivity, holding real promise for early disease detection, accurate profiling, and truly personalized treatment strategies. Therapeutic genome editing, meanwhile, offers the potential for targeted interventions in genetic disorders that were previously considered incurable, further reinforcing demand for synthetic biology tools within the therapeutic development pipeline.
High costs remain a significant barrier, however. The complexity of synthetic biology techniques, combined with the need for specialized equipment, skilled personnel, and extensive laboratory infrastructure, drives up costs across the value chain. In response, companies are increasingly turning to fermentation of plant-based feedstock — a method reminiscent of brewing and pharmaceutical yeast-based production — to reduce reliance on scarce raw materials. As firms gain expertise in this area, they are expanding into manufacturing both simple and increasingly complex materials, from bioactive compounds to sustainable alternatives for leather and specialty chemicals.
Emerging Trends
Advances in gene and cell therapy represent one of the field’s most consequential trends. Techniques such as CAR-T cell therapy are transforming cancer treatment by harnessing the body’s own immune system to target malignant cells, while CRISPR-Cas9 technology continues enabling increasingly precise genomic modifications that hold promise for correcting the root causes of genetic disorders at the molecular level. These developments are drawing substantial investment and research attention as the field continues to demonstrate its potential to address complex medical challenges.
The emergence of next-generation, high-throughput synthetic biology technologies is also reshaping the pace of innovation. These platforms prioritize rapid design-build-test-learn cycles, accelerating the development of artificial systems with predictable functions across health, chemicals, medicine, environmental applications, and biofuels. Key enabling technologies — genome design, microfluidics, cell-free systems, and genome editing — are together supporting increasingly precise manipulation of genetic material and efficient synthesis of biological components, expanding the range of viable commercial applications.
Segmentation Insights
By technology, the market spans NGS technology, PCR technology, genome editing technology, bioprocessing technology, and others, with PCR technology leading in 2023 at a valuation of USD 5.05 billion. Real-time PCR has become deeply embedded in genomic research thanks to its specificity and sensitivity, powering applications ranging from pathogen and mutation detection in molecular diagnostics to DNA profiling in forensic science and gene expression studies in broader genomics research.
By product, the market covers oligonucleotides, enzymes, cloning technologies kits, xeno-nucleic acids, and chassis organisms, with oligonucleotides projected to reach USD 22.21 billion by 2031. These serve as foundational components across targeted next-generation sequencing, mutagenesis experiments, DNA computing, and CRISPR-based gene editing, with rising adoption of custom-designed oligonucleotides for targeted genomic amplification and sequencing driving continued segment expansion.
By end user, the market is classified into biotechnology and pharmaceuticals companies, academic and government research institutes, and others, with the biotechnology and pharmaceuticals segment expected to grow at a 21.59% CAGR through the forecast period. These sectors are major drivers of adoption, leveraging synthetic biology for drug discovery, biologic production optimization, and personalized medicine, including engineered microbes for bio-based chemical production and synthetic gene circuits for targeted therapeutic interventions.
Regional Outlook
North America led the global synthetic biology market in 2023, capturing approximately 38.49% of total share with a valuation of USD 6.59 billion. Substantial investment in DNA sequencing, genome editing tools such as CRISPR-Cas9, and computational biology — particularly within the United States — continues to foster innovation across pharmaceuticals, biomanufacturing, and agriculture, supported further by a favorable regulatory framework across the region.
Asia-Pacific is projected to be the fastest-growing region, expanding at a 23.16% CAGR through the forecast period. Technological progress, rising investment, and growing awareness of biotechnology’s transformative potential are fueling this trajectory, with government initiatives in countries such as India and continued advances in genome mapping and bioinformatics accelerating adoption of synthetic biology applications across the region.
Competitive Landscape
The synthetic biology market remains fragmented, with leading companies including Thermo Fisher Scientific Inc., Synbio Technologies, Merck KGaA, Agilent Technologies Inc., GenScript, Novozymes, Codexis, Inc., Bota Biosciences Inc., Illumina, Inc., and Synthego competing through continuous technological innovation, strategic partnerships, and expanding manufacturing infrastructure.
Recent industry activity underscores this momentum. In July 2023, Sumitomo Chemical Co., Ltd. and Ginkgo Bioworks announced a joint venture aimed at leveraging synthetic biology to develop useful chemicals, building on their existing biomanufacturing partnership. In May 2023, Ginkgo Bioworks and Octarine Bio launched a multi-phase collaboration focused on engineering microbial strains capable of producing violacein and related tryptophan-derived compounds prized for their antioxidant, antibacterial, and UV-protective properties, illustrating the range of novel bio-based products emerging from this collaborative innovation model.
Outlook
With the biotechnology and pharmaceuticals end-user segment expected to grow fastest and Asia-Pacific set to lead regional expansion, the synthetic biology market appears firmly positioned for sustained, rapid growth through 2031. As DNA synthesis and gene editing costs continue to fall and applications expand across healthcare, agriculture, and industrial manufacturing, synthetic biology looks set to remain one of biotechnology’s most dynamic growth frontiers.
